Avaleht › 2. tüüpi diabeet › Alabama › Birmingham
2. tüüpi diabeet kliinilised uuringud linnas Birmingham, AL
16 uuringut haiguse 2. tüüpi diabeet jaoks otsivad osalejaid linnas Birmingham ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
Värbamine
- University of Alabama, Birmingham
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
Värbamine
- University of Alabama, Birmingham
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
VärbamineFaas 3
- Cahaba Research, Inc. - Trussville Location, Birmingham
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
VärbamineFaas 3
- Birmingham Clinical Research, Birmingham
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
VärbamineFaas 3
- AURORA-2 Clinical Site, Birmingham
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
VärbamineFaas 2
- Central Research Associates - Flourish - PPDS, Birmingham
- AES - DRS - Synexus Clinical Research US, Inc. - Birmingham, Birmingham
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
VärbamineFaas 2
- Flourish Research, Birmingham
Advancing Diabetes Management for People With Physical Disabilities Optimally Through Primary Care-Based Telehealth (ADDOPT)
Värbamine
- UAB Highlands Hospital/Department of Family and Community Medicine, Birmingham
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
VärbamineFaas 3
- Research Site, Birmingham
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
VärbamineFaas 3
- Univ of Alabama Birmingham, Birmingham
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
VärbamineFaas 3
- Research Site, Birmingham
CGM for Management of Type 2 Diabetes in Pregnancy
Värbamine
- University of Alabama at Birmingham, Birmingham
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
VärbamineFaas 2
- Central Research Associates, LLC dba Flourish Research, Birmingham
DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
VärbamineVaatlusuuring
- University of Alabama at Birmingham, Birmingham
FELLAShip to Better Health
Värbamine
- The Worship Center Cristian Church, Birmingham
A Low-Carb Approach to Treat Type 2 Diabetes in Pediatric Patients
Värbamine
- University of Alabama at Birmingham/ Children's of Alabama, Birmingham
2. tüüpi diabeet uuringud teistes linnades
- San Antonio, TX37 uuringut
- Houston, TX31 uuringut
- Orlando, FL24 uuringut
- Boston, MA20 uuringut
- Miami, FL19 uuringut
- Chicago, IL19 uuringut
- Dallas, TX19 uuringut
- Columbus, OH18 uuringut
- Las Vegas, NV18 uuringut
- Atlanta, GA17 uuringut
- San Diego, CA17 uuringut
- Los Angeles, CA16 uuringut
Muud uuringud linnas Birmingham
- Vähk (kõik liigid)30 uuringut
- Rinnavähk24 uuringut
- Rasvumine23 uuringut
- Munasarjavähk23 uuringut
- Mitteväikerakuline kopsuvähk22 uuringut
- Äge müeloidne leukeemia21 uuringut
- Müeloom18 uuringut
- KOKH17 uuringut
- Kardiovaskulaarsed haigused17 uuringut
- Ülekaalulisus16 uuringut
- Endomeetriumivähk16 uuringut
- Tsüstiline fibroos16 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.